Takeda Pharmaceutical Company Limited reported JPY 4.58T of revenue over the trailing twelve months, +7.5% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: JPY 4.58T (to FY2025). Net income: JPY 107.9B, trailing twelve months to FY2025. Free cash flow: JPY 856.4B, trailing twelve months to FY2025. Operating margin: 7.5%, trailing twelve months to FY2025.

TAKTakeda Pharmaceutical Company Limited

Healthcare

$18.73+24% 1Y

$18.73

$13.2352 weeks$19.05

TAK as reported

Takeda Pharmaceutical Company Limited reported JPY 4.58T of revenue over the trailing twelve months, +7.5% on the year before. 10 reported series are charted on this page, each one as filed.

JPY 4.58T

Revenue, trailing twelve months · to FY2025 · +7.5% against the twelve months before

Net income: JPY 107.9B
Net income · −25% year on year · trailing twelve months to FY2025
Free cash flow: JPY 856.4B
Free cash flow · +58% year on year · trailing twelve months to FY2025
Operating margin: 7.5%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for TAK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	JPY 4.58T	+7.5%	FY2025
Net income	JPY 107.9B	−25%	FY2025
EPS	JPY 67.23	−26%	FY2025
Gross margin	66%	n/a	FY2025
Operating margin	7.5%	n/a	FY2025
Net margin	2.4%	n/a	FY2025
ROE	1.6%	n/a	FY2025
ROA	0.76%	n/a	FY2025
ROIC	2.4%	n/a	FY2025
Free cash flow	JPY 856.4B	+58%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.